Sun Pharma's stock recently broke out of a consolidation range set since March 2024, hitting a new record high of Rs 1722. Experts recommend short-term traders to buy with a target above Rs 1,900 within 1-2 months as the stock rallied over 50% in three months but entered the oversold zone, signaling potential consolidation.
